Form 4: Cytokinetics CEO Exercises Options and Sells Shares

Cytokinetics CEO Robert I. Blum exercised stock options and sold shares on December 2, 2024.

Summary

• On December 2, 2024, Cytokinetics CEO Robert I. Blum exercised 5,000 stock options at a price of $6.67 per share.
• Following the exercise of options, Mr. Blum sold 5,000 shares of common stock at a price of $50.76 per share.
• After these transactions, Mr. Blum directly owns 397,678 shares of Cytokinetics common stock.
• Mr. Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
• Mr. Blum also holds 54,727 non-qualified stock options.

Sentiment

Score: 5

Explanation: This is a neutral transaction, reflecting routine executive compensation and portfolio management. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing for insider transactions and is common for executives who hold stock options and equity in their companies. It does not indicate any specific trend in the biotechnology industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are typical for executives who receive stock options as part of their compensation.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a small number of shares compared to the total outstanding shares.

Key Dates

Keywords

Cytokinetics, stock options, insider trading, Form 4, Robert I. Blum, CEO, share sale, equity securities